• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Chemother . Potential usage of anterior nasal sampling in clinical practice with three rapid antigen tests for SARS-CoV-2

tetano

Editor, Senior Moderator
J Infect Chemother


. 2022 Sep 8;S1341-321X(22)00254-9.
doi: 10.1016/j.jiac.2022.09.001. Online ahead of print.
Potential usage of anterior nasal sampling in clinical practice with three rapid antigen tests for SARS-CoV-2


Hidetoshi Nomoto[SUP] 1 [/SUP], Kei Yamamoto[SUP] 2 [/SUP], Erina Isaka[SUP] 3 [/SUP], Yusuke Miyazato[SUP] 4 [/SUP], Tetsuya Suzuki[SUP] 1 [/SUP], Taketomo Maruki[SUP] 4 [/SUP], Gen Yamada[SUP] 4 [/SUP], Kohei Kamegai[SUP] 4 [/SUP], Yutaro Akiyama[SUP] 4 [/SUP], Satoshi Ide[SUP] 5 [/SUP], Masami Kurokawa[SUP] 3 [/SUP], Ataru Moriya[SUP] 3 [/SUP], Kazuhisa Mezaki[SUP] 3 [/SUP], Shintaro Yagi[SUP] 6 [/SUP], Hisashi Nojima[SUP] 6 [/SUP], Kentaro Yamakawa[SUP] 6 [/SUP], Norio Ohmagari[SUP] 1 [/SUP]



Affiliations

Abstract

Introduction: Anterior nasal sampling (AN) might be more convenient for patients than NP sampling to diagnose coronavirus disease. This study investigated the feasibility of rapid antigen tests for AN sampling, and the factors affecting the test accuracy.
Methods: This single-center prospective study evaluated one qualitative (ESP) and two quantitative (LUMI and LUMI-P) rapid antigen tests using AN and NP swabs. Symptomatic patients aged 20 years or older, who were considered eligible for reverse-transcription quantitative polymerase chain reaction using NP samples within 9 days of onset were recruited. Sensitivity, specificity, and positive and negative concordance rates between AN and NP samples were assessed for the rapid antigen tests. We investigated the characteristics that affected the concordance between AN and NP sampling results.
Results: A total of 128 cases were recruited, including 28 positive samples and 100 negative samples. The sensitivity and specificity of AN samples using ESP were 0.81 and 1.00, while those of NP samples were 0.94 and 1.00. The sensitivity of AN and NP samples was 0.91 and 0.97, respectively, and specificity was 1.00, for both LUMI and LUMI-P. The positive concordance rates of AN to NP sampling were 0.87, 0.94, and 0.85 for ESP, LUMI, and LUMI-P, respectively. No factor had a significant effect on the concordance between the sampling methods.
Conclusions: ESP, LUMI, and LUMI-P showed practical diagnostic accuracy for AN sampling compared to NP sampling. There was no significant factor affecting the concordance between AN and NP sampling for these rapid antigen tests.

Keywords: COVID-19; Espline; Lumipulse; SARS-CoV-2; anterior nasal; rapid antigen test.
 
Back
Top Bottom